H emopoietic stem and progenitor cells (HPC), 5 which usually reside within bone marrow (BM), can be released into circulation after treatment with cytokines, cytotoxic agents, or both (1) . Among a number of agents, G-CSF is the cytokine most commonly used clinically to mobilize HPC in a variety of transplantation settings because of its potency and lack of serious toxicity. Especially in allogeneic stem cell transplantation, G-CSF-mobilized peripheral blood stem and progenitor cells (PBPC) now are replacing marrow-derived HPC as a stem cell source.
G-CSF acts by binding to its receptor (G-CSFR), a member of the class I cytokine receptor family expressed on various hemopoietic cells such as stem cells, multipotent progenitors, myeloidcommitted progenitors, neutrophils, and monocytes (2-4). Liu et al. (5) showed a significant effect of G-CSF signals on HPC mobilization by demonstrating that mice deficient in G-CSFR failed to mobilize HPC in response to G-CSF. Conversely, they also reported that chimeric mice with both wild-type and deleted G-CSFR can mobilize equal numbers of HPC with or without the receptor in response to G-CSF (6) . Thus, G-CSFR expression on HPC may not be crucial for their mobilization by G-CSF. These data indicate that G-CSF can induce HPC mobilization by pathways not limited to transmittal of G-CSF signals directly onto the target cells. Recent insights using experimental animal models are provided suggesting that HPC mobilization by G-CSF could be mediated by indirect effects involving generation of multiple transacting signals in the marrow microenvironment (7) (8) (9) (10) (11) . Proteolytic enzymes such as neutrophil elastase, cathepsin G, and matrix metalloproteinase (MMP)-9 released from the activated neutrophils and monocytes can degrade and/or inactivate the adhesion molecules such as VCAM-1/VLA-4, chemokines such as stromal-derived factor (SDF)-1/CXCR-4, and soluble Kit ligand, resulting in the disruption of contact between HPC and the BM microenvironment. HPC then would be released to migrate into peripheral blood (PB). However, details of the mechanisms of HPC mobilization by G-CSF are not yet fully understood, especially in humans.
Marrow is the primary lymphohematopoietic organ where B lymphoid lineage development occurs. Under ordinary steady-state conditions, immature lymphoid progenitors in various stages of differentiation as well as multipotent and myeloid progenitors are confined to BM microenvironments in which they undergo further differentiation; then the mature cells leave the BM and circulate in the blood. In this context, considering the broad spectrum of target cells affected by G-CSF and involvement of changes affecting adhesion molecules in HPC mobilization, G-CSF might be expected to mobilize not only G-CSFR-possessing cells but a variety of cell populations including lymphoid cells and nonhematopoietic cells residing within the BM. Accordingly, we evaluated populations of G-CSF-mobilized blood cells in detail using multicolor flow cytometry to better understand the mechanism of G-CSF-induced mobilization in humans. We identified small but significant populations possessing immature lymphoid phenotypes such as
ϩ cells among G-CSF-mobilized cells in blood; these have been defined as early B and pro-B cells in the BM, respectively. The mobilized CD34 ϩ CD10 ϩ CD19 Ϫ and CD34 ϩ CD10 ϩ CD19 ϩ cells are capable of differentiation into B/NK cells or B cells that are equivalent to their BM counterparts. Furthermore, these mobilized lymphoid progenitors express lymphoid-related genes but not myeloid-affiliated genes including G-CSFR. In addition, Ig gene rearrangements were detected in these mobilized progenitors. Expression of adhesion molecules such as VLA-4 and CXCR-4 on the mobilized lymphoid progenitors as well as multipotent and myeloid progenitors was down-regulated compared with their steady-state BM and even G-CSF-treated BM counterparts. Thus, G-CSF can mobilize not only myeloid progenitors but also early B and pro-B progenitor cells by modulation of adhesion molecules in a lineage-independent manner. These findings also support the hypothesis that G-CSF can mediate HPC mobilization indirectly in humans as well as mice.
Materials and Methods

Patients
G-CSF-mobilized PB samples were collected from 82 healthy allogeneic PBPC donors who received G-CSF (Filgrastim; Kirin) s.c. at 400 g/m 2 per day for 5 days. G-CSF-treated BM samples also were collected from three of these volunteer donors on day 5 of G-CSF administration. Steadystate BM and PB samples were collected from 14 and 34 healthy adults, respectively. Informed consent was obtained from all subjects.
Cell preparation and staining
PB and BM mononuclear cells (MNC) were prepared by gradient centrifugation. For analysis of myeloid progenitor cells, cell samples were stained with a Cy5-PE-conjugated lineage (Lin) mixture (anti-CD3, -CD4, -CD8, -CD11b, -CD16, -CD20, -CD56, and glycophorin A; Caltag Laboratories), FITC-conjugated anti-CD13 (BD Pharmingen), PE-conjugated anti-CD33 (BD Pharmingen), allophycocyanin-conjugated anti-CD34 (BD Pharmingen), and biotin-conjugated anti-CD38 (Caltag Laboratories) Abs. B lymphoid progenitors were stained with the same Cy5-PE-conjugated lineage mixture followed by FITC-conjugated anti-CD10 (Ancell), PE-conjugated anti-CD19 (BD Pharmingen), and anti-CD38 and -CD34 as described above. For analysis of T-lymphoid progenitors, Lin Ϫ cells were stained with FITC-conjugated anti-CD7 (BD Pharmingen), PE-conjugated anti-CD2 (BD Pharmingen), and anti-CD38 and -CD34 as described above. Streptavidin-conjugated Cy7-allophycocyanin (Caltag Laboratories) were used for visualization of biotinylated Abs. Nonviable cells were excluded by propidium iodide staining. Expression of adhesion molecules was detected on progenitors staining by PE-conjugated anti-CXCR-4, VLA-4, and c-Kit (BD Pharmingen), together with anti-CD10 or -CD13 and anti-CD38 and -CD34 as described above.
For sorting cells, CD34 ϩ cells were enriched from MNC using immunomagnetic beads according to the manufacturer's instructions (CD34 ϩ selection kit; Miltenyi Biotec) followed by staining specific for progenitors of each lineage as described above. CD34
Lin
Ϫ early B cells, and CD34
Ϫ pro-B cells were sorted by a highly modified triple laser (488-nm argon laser, 633-nm helium-neon laser, and UV laser) FACS (FACSVantage SE; BD Pharmingen). Five-color sorting using both positive and negative gates in multiple channels usually gives rise to cells with Ͼ98% purity, avoiding cosorted cells stained in a nonspecific manner. The sorted cells were subjected to an additional round of sorting using the same gate to eliminate contaminating cells and doublets (12) .
In vivo and in vitro assays to determine differentiation potential
Clonogenic progenitor assay was performed using a methylcellulose culture system as reported previously (12, 13) . Cells also were cultured on the irradiated Sys-1 or MS-5 stromal cell layers (14, 15) . Human cytokines such as stem cell factor (SCF) (20 ng/ml), IL-3 (30 ng/ml), IL-2 (50 ng/ml), GM-CSF (20 ng/ml), erythropoietin (2 U/ml), thrombopoietin (20 ng/ml; Kirin), IL-7 (20 ng/ml), flt3/flk2-ligand (FL; 10 ng/ml), and IL-11 (10 ng/ ml; R&D Systems) were added at the start of the culture.
Long-term culture initiating-cell (LTC-IC) assays were performed in human long-term culture medium (Myelocult H5100; StemCell Technologies) supplemented with hydrocortisone on irradiated M2-10B4 stromal layers as described previously (13) . At 6 wk of culture on the stromal layers, cells were transferred to the methylcellulose medium, and colonies were counted 14 days later.
For limiting dilution analysis, variable numbers of double-sorted early B cells were deposited on the MS-5 stromal cell layers in the presence of IL-7, IL-11, SCF, FL, and IL-2, using an automatic cell deposition unit system (BD Pharmingen). All cultures were incubated at 37°C in a humidified atmosphere including 7% CO 2 .
For reconstitution assays, FACS-sorted cells were injected into irradiated (350 rad) NOD/SCID/␤ 2 -microglobulin knockout (NOD/SCID/ ␤2 Ϫ/Ϫ ) mice as described previously (16) . At 6 -8 wk after transplantation, BM and spleen were collected for analysis by flow cytometery. Cells were stained with mAbs to human leukocyte differentiation Ags, including CD45, CD19, CD10, CD15, CD56, and CD3.
Gene expression profile by RT-PCR
To examine gene expression profile of each population, total RNA was purified from 1000 double-sorted cells and was amplified by RT-PCR (12) . The primer sequences were reported previously (13) . PCR products were electrophoresed on an ethidium bromide-stained 2.0% agarose gel. PCR amplification was repeated at least twice for at least two separately prepared samples.
PCR analysis of IgH gene rearrangement
To analyze IgH gene rearrangements status of each population, DNA was extracted from double-sorted 5000 cells, and PCR amplification of VDJ H and DJ H rearrangement was performed as described previously (17, 18) . This PCR analysis can detect incomplete DJ H rearrangements of IgH gene with a mixtures of upstream D H primers and a consensus J H primer, resulting in a ladder of different sized products ranging from 70 to 100 bp depending on the length of the DJ H rearrangements. The GAPDH gene primers were used as control for DNA integrity.
Statistical analyses
Levels of significance were measured using paired t test. p Ͻ 0.05 was considered significant.
Results
Phenotypic analysis
Using a five-color cell sorter, we analyzed the distribution of each cell population including multipotent, myeloid, and lymphoid progenitors. Under unstimulated conditions, few CD34
ϩ Lin Ϫ cells circulated in the periphery (0.023 Ϯ 0.014% of MNC; n ϭ 34), whereas the number of circulating CD34
ϩ Lin Ϫ cells increased up to 0.59 Ϯ 0.35% of MNC after G-CSF administration (Table I) . CD34
ϩ Lin Ϫ fractions are subdivided into two fractions according to expression of CD38: CD34 ϩ CD38 Ϫ/low Lin Ϫ fractions contain hemopoietic stem cells with multipotent, self-renewing capacity, whereas CD34 ϩ CD38 ϩ Lin Ϫ cells include lineage-committed progenitors that have lost self-renewing capacity (Fig. 1A) (13) .
In BM, G-CSF administration increased the number of MNC up to ϳ2.4-fold, with dominant expansion of myeloid-committed progenitors and mature granulocytes/macrophages; this reflected a relatively reduced percentage of the primitive CD34
Lin Ϫ cells were mobilized into the periphery by G-CSF, their percentage was significantly lower than in steady-state BM (Table I) 
Lin
Ϫ cells in BM and PB, respectively (Table I and Fig. 1B ). These data showed that myeloid-committed progenitors expanded within BM and were the main population mobilized by G-CSF administration.
Lymphoid progenitors mobilized by G-CSF
Under ordinary conditions, after commitment to the B lymphoid differentiation pathway,
Ϫ early B cells or common lymphoid progenitors (CLP) (14, 19) and differentiate within (Fig. 1A) (20) . Then mature B cells are released from the BM into the circulation. In our analysis, early B and pro-B cells were undetectable in the PB of 34 healthy volunteers (data not shown). In the steady-state BM, early B cells and pro-B cells comprised 0.82 Ϯ 0.56% and 8.93 Ϯ 5.37% of CD34 ϩ CD38 ϩ Lin Ϫ cells, respectively (n ϭ 14; Table I ). Following G-CSF administration, despite the relatively reduced percentage of lymphoid progenitors reflecting expansion of myeloid lineage cells, absolute numbers of early B and pro-B cells in BM were not significantly different from those in steady-state BM (Table I) . Surprisingly, the G-CSF-mobilized PB contained small but significant populations possessing the same lymphoid phenotypes as BM early B and pro-B cells in the CD34 ϩ CD38 ϩ Lin Ϫ fractions: CD10 ϩ CD19 Ϫ and CD10 ϩ CD19 ϩ cells were detectable in 60 and 80 of 82 cases, respectively. A representative FACS analysis is shown in Fig. 1B . These CD10 ϩ CD19 Ϫ and CD10 ϩ CD19 ϩ cells constituted 0.14 Ϯ 0.09% (0 -0.68%) and 1.49 Ϯ 1.30% (0 -8.58%) of CD34 ϩ CD38 ϩ Lin Ϫ cells, and ϳ0.001% and 0.01% of G-CSF-mobilized PB MNC, respectively (Table I ). The percentage of circulating lymphoid progenitors was 10 and 6 times less than that in steady-state BM and in G-CSF-treated BM, respectively. T-lineage progenitor coexpressing CD34 and CD7 or CD2 was undetectable in the G-CSF-mobilized PB (data not shown). These lymphoid progenitors were doubly sorted and subjected to analyses of differentiation capacity and gene expression profiles as follows.
Change in expression of adhesion molecules during G-CSF mobilization
We next evaluated expression of c-Kit and adhesion molecules such as VLA-4 and CXCR-4 on different progenitors during G-CSF administration. Fig. 2 shows the mean fluorescence intensity (MFI) for these molecules among MPP, myeloid progenitors, and lymphoid progenitors.
Under physiological conditions, c-Kit was expressed at a low level on the BM CD34 ϩ CD38 Ϫ/low Lin Ϫ primitive MPP. Its expression was up-regulated in myeloid progenitors but shut down in CD10 ϩ lymphoid progenitors (Fig. 2A) ; these results are consistent with those reported previously (14, 21) . CXCR-4, a receptor for SDF-1 that is critical for homing of HPC as well as B lymphopoiesis (22) , was highly expressed on lymphoid progenitors, whereas MPP and myeloid progenitors showed low CXCR-4 expression (Fig. 2B) . VLA-4 was expressed on all three types of progenitors; frequency of expression did not differ significantly among them (Fig. 2C) .
Following G-CSF administration, MFI for c-Kit expression on MPP and myeloid progenitors was decreased in PB compared with that in steady-state BM ( Fig. 2A) . In contrast, lymphoid progenitors showed low to absent c-Kit expression, and MFI between the tissues was not different. As shown in Fig. 2 , B and C, MFI for CXCR-4 and VLA-4 expression for all three progenitor types in BM declined after G-CSF administration; further decrease was observed in the G-CSF-mobilized progenitors. These results suggest that adhesion molecule expression on HPC in BM decreased during G-CSF administration in a lineage-independent manner. As a result, a fraction of cells with lesser expression of these molecules may be mobilized into the circulation. (Fig. 3, A and B) . In contrast, early B cells sorted from BM and G-CSF-mobilized PB gave rise to CD10 ϩ CD19 ϩ pro-B cells and CD10 Ϫ CD19 ϩ pre-B cells as well as NK cells but not myeloid cells (Fig. 3, C 
Mobilized lymphoid cells are restricted to B/NK cell lineage
, D, G, and H). Pro-B cells from BM and G-CSF-mobilized PB also formed CD19
ϩ B cell-containing colonies, but neither myeloid nor NK cells were detected in cultured cells (Fig. 3, E, F, I , and J).
Production of T cells was not observed in any of these cultures (data not shown). Six to 8 wk after transplantation of FACS-sorted progenitors into irradiated NOD/SCID/␤2
Ϫ/Ϫ mice, animals were sacrificed to assess reconstitution of human hematopoiesis. FACS analysis of spleen and BM cells showed the presence of human CD45 ϩ cells in all mice transplanted with 50,000 CD34 
Lin
Ϫ cells could differentiate into myeloid cells, B cells, and NK cells in these mice (Fig. 4A) . In contrast, mice transplanted with 50,000 pro-B cells sorted from BM or G-CSF-mobilized PB exhibited only B lymphoid reconstitution (Fig.  4B) . However, human CD45 ϩ cells could not be detected in animals transplanted with up to 3000 CD34 
Lymphoid progenitors have no self-renewing capacity
To test limited self-renewal activity, BM and G-CSF-mobilized early B and pro-B cells were plated in limiting dilution in LTC-IC assays and transferred to methylcellulose after 6 wk of culture as described previously (13) . The estimated frequency of LTC-IC 
Differentiation potential of early B cells in limiting dilution analysis
We next evaluated B cell differentiation capacity of BM and G-CSF-mobilized early B cells at limiting dilution in culture on MS-5 stromal cell layers, which can support differentiation of B lymphoid progenitors from human CD34 ϩ cells (15) . As shown in Fig.  3 , early B cells were capable of differentiation into CD10 ϩ CD19 ϩ pro-B cells and CD10 Ϫ CD19 ϩ pre-B cells after 4 wk of culture under this condition. In a limiting dilution assay, we estimated that one in eight BM early B cells and one in 10 G-CSF-mobilized early B cells could read out B cell differentiation in this culture condition (Fig. 5) . Frequency of B cell development did not differ significantly between BM and G-CSF-mobilized early B cells.
Mobilized lymphoid progenitors show lineage-specific gene expression profiles
We tested expression of several genes in early B and pro-B cells sorted from the G-CSF-mobilized PB and BM by RT-PCR. Lymphoid lineage-specific genes such as IL-7R, TdT, Pax-5, and VpreB were expressed in early B and pro-B cells from both BM and G-CSF-mobilized PB (Fig. 6 ). Granulocyte lineage-related genes including G-CSFR, GM-CSF receptor, and myeloperoxidase were not detected in early B or pro-B cells from either BM or G-CSF-mobilized PB (Fig. 6) .
IgH rearrangement in G-CSF-mobilized B lymphoid progenitors
We examined the IgH rearrangement status in the mobilized B lymphoid progenitors, because Ig genes rearrangement status reflect well the differential stages in the B cell development pathway. In general, along with B cell differentiation pathway, Ig genes rearrangements proceed from DJ H at the early B cells or CLP stage through VDJ H at the pro-B cells stage and to L chain gene at the pre-B cells stage (17, 20, 23, 24) .
In our experiments, DJ H and VDJ H rearrangements were undetectable in the most immature CD34 ϩ CD38 Ϫ Lin Ϫ cells sorted from both BM and the G-CSF-mobilized PBPC. In contrast, a ladder of DJ H rearrangement bands ranging from 70 bp to 100 bp was observed in BM and G-CSF-mobilized CD34 ϩ CD10 ϩ CD19
Ϫ early B cells (Fig. 7) . VDJ H and DJ H rearrangements were detected in both BM and G-CSF-mobilized CD34 ϩ CD10 ϩ CD19 ϩ pro-B cells. The mobilized B lymphoid progenitors undergo IgH gene rearrangements in parallel with their BM counterparts.
Discussion
In this study, using multicolor flow cytometry, we demonstrated that administration of G-CSF to human subjects induced mobilization into PB of tiny but significant cell populations possessing the same immature lymphoid phenotypes as those of B/NK and B lymphoid-committed progenitors that are well defined in the BM. administration, activated neutrophils and monocytes release proteolytic enzymes such as neutrophil elastase, cathepsin G, and MMP-9, which cleave and/or inactivate adhesion molecules expressed on the HPC (25) (26) (27) (28) (29) (30) (31) . In fact, decreased expression of VLA-4 (32-35), CXCR-4 (28, 36) , and c-Kit (30, 37, 38) on mobilized HPC has been reported during G-CSF administration in humans. Altered expression of adhesion molecules and consequent modification of their adhesion capacity might lead to release and migration of HPC into the circulation (7) (8) (9) (10) (11) . Our study showed decreased expression of VLA-4 and CXCR-4 on circulating progenitors including MPP, myeloid, and lymphoid progenitors following G-CSF administration compared with that of BM, suggesting possible involvement of adhesion molecules in mobilization of at least three different types of immature progenitors. However, the extent to which each of these molecules contributed to mobilization of each hemopoietic lineage (11), or whether specific adhesion molecules are modulated in a lineage-dependent fashion, was not clear. Among the adhesion molecules that we examined, a dramatic decrease was observed in CXCR-4 expression on the lymphoid progenitors mobilized by G-CSF administration. SDF-1/ CXCR-4 interactions also are involved in B lymphopoiesis, as substantiated by studies in CXCR-4-deficient mice that demonstrated reduced numbers of B lymphoid progenitors in the BM but abnormally high numbers of B lymphoid progenitors as well as the presence of mature B cells in blood and spleen (22, 39, 40) . This suggests that CXCR-4 is required to retain B lymphoid progenitors within BM microenvironment for further maturation, as opposed to direct signaling to promote B cell development. These results agree with our findings that despite reduced expression in CXCR-4, the same differentiation capacity was preserved in mobilized lymphoid progenitors as their counterparts had in the steady-state BM. Thus, a decrease in CXCR-4 expression could be induced in a lineage-independent fashion following G-CSF, with resulting modulations contributing to migration of HPC without loss or alteration of differentiation capacity.
Importantly, hemopoietic growth factors can affect growth and/or properties of hemopoietic progenitors and cells. G-CSF has been characterized as a pivotal cytokine in proliferation, maturation, and survival in the myeloid lineage development pathway. Thus, G-CSF may affect potential or manifest characteristics of HPC during G-CSF mobilization, and HPC may have different abilities to develop and function. For example, mobilized CD34 ϩ cells have been reported to show decreased cell cycling compared with their BM counterparts (38, 41) . In addition, numerous recent studies have demonstrated differentiation plasticity of committed progenitors, suggesting that hemopoietic progenitors retain a latent trans differentiation potential making them susceptible to diversion from their developmental fate (42-46). These observations suggest that circulating B lymphoid progenitors exposed to extremely high concentrations of G-CSF might show a different potential than their BM counterparts under physiological conditions, or might be trans-differentiated from other lineages. In our analysis, expression of B lineage-specific differentiation programs was preserved, and no myeloid genes were activated in G-CSF-mobilized lymphoid progenitors. By limiting dilution assay, we also demonstrated that the B cell differentiation potential of G-CSF-mobilized lymphoid progenitors was equivalent to that of their BM counterparts. Thus, G-CSF can mobilize B lymphoid progenitors without loss or alteration of the original characteristics of B lymphoid progenitors in BM. For that reason, B lymphoid progenitors, as opposed to all CD34 ϩ cells or myeloid cells, represent a good population for analysis of mechanisms of G-CSF-induced mobilization, because, lacking the receptor, lymphoid progenitors would be less affected by G-CSF signals during mobilization.
Recent insights have increased understanding of the important role of the BM microenvironment, or niche, in retention and development of HPC within the BM. Regulation of cell-fate determination and trafficking of the primitive HPC may be governed by complex interactions between HPC and the surrounding BM niche (47, 48) . As discussed above, SDF-1/CXCR-4 signaling is crucial for retention of B lymphoid progenitors within the BM, which can support further B cell development within the BM microenvironment (22, 39, 40) . However, whether G-CSF can change BM microenvironments themselves to promote or inhibit HPC mobilization remains largely unknown. Our findings indicated that G-CSF can mobilize cell populations that do not possess G-CSFR from the BM into the circulation. Accordingly, G-CSF-mobilized blood cells can include a variety of populations such as mesenchymal stem and progenitor cells, which can differentiate into nonhematopoietic cells such as vascular endothelial cells, cardiac muscle cells, and hepatocytes. Such mobilized blood cells conceivably might serve as a therapeutic agent in the treatment of various degenerative disorders as opposed to BM cells as a stem cell source (49) . Up to now, G-CSF has been the HPC mobilizer of choice in clinical settings, based upon its potency and safety. However, poor mobilization has been reported in ϳ10 -20% of healthy donors, representing a major problem (50, 51) . To address these unresolved issues, further investigation of mechanisms of G-CSF-induced mobilization may lead to more effective and safer mobilization methods and agents, and clarify the usefulness of G-CSF-mobilized PB cells as an alternative source of a variety of cells for regenerative medicine.
In summary, our data provide further evidence for an indirect effect of G-CSF on human HPC mobilization by demonstrating mobilization of lymphoid progenitors. Lineage-independent modulation of adhesion molecules such as VLA-4 and CXCR-4 might be involved in G-CSF-induced mobilization. These findings suggest that G-CSF can mobilize not only HPC but also nonhematopoietic cells residing in the BM by indirect effects involving multiple trans-acting signals that affect cell interactions with the marrow microenvironment. 
